The U.S. Food and Drug Administration (FDA) recently issued revised draft guidance focusing on the dissemination of scientific information about unapproved uses of approved/cleared medical devices and pharmaceuticals to healthcare providers (HCPs). This was a much anticipated move, taking place on October 23, 2023.
In previous years, guidance regarding this matter had been somewhat ambiguous, leading to uncertainty among HCPs and impacting decision-making related to off-label uses. This latest directive from the FDA aims to address this ongoing issue within the medical and pharmaceutical sectors.
The exact implications and outcomes of this guidance revision yet remain to be seen and will likely develop over the following months as industry professionals, legal teams, and HCPs begin to adapt and adhere to the new standards set forth by the FDA.